Close
  Indian J Med Microbiol
 

Figure 2: Placebo-corrected mean changes in glycated hemoglobin (HbA1c) from baseline over 24 weeks (full analysis set-last observation carried forward) mean baseline HbA1c values: Placebo = 8.92 ± 1.04%, metformin 500 mg = 8.84 ± 1.02%, metformin 1000 mg = 8.69% ± 0.96%, linagliptin 5 mg = 8.98 ± 1.17%, linagliptin 2.5 mg + metformin 500 mg = 8.96% ± 1.12%, and linagliptin 2.5 mg + metformin 1000 mg = 9.03 ± 0.98%. MET = Metformin, LIN = Linagliptin, HbA1c = Glycated hemoglobin, LOCF = Last observation carried forward, FAS = Full analysis set (all patients in the total set who had a baseline and at least one on-treatment HbA1c value)

Figure 2: Placebo-corrected mean changes in glycated hemoglobin (HbA1c) from baseline over 24 weeks (full analysis set-last observation carried forward) mean baseline HbA1c values: Placebo = 8.92 ± 1.04%, metformin 500 mg = 8.84 ± 1.02%, metformin 1000 mg = 8.69% ± 0.96%, linagliptin 5 mg = 8.98 ± 1.17%, linagliptin 2.5 mg + metformin 500 mg = 8.96% ± 1.12%, and linagliptin 2.5 mg + metformin 1000 mg = 9.03 ± 0.98%. MET = Metformin, LIN = Linagliptin, HbA1c = Glycated hemoglobin, LOCF = Last observation carried forward, FAS = Full analysis set (all patients in the total set who had a baseline and at least one on-treatment HbA1c value)